GRAIL, Inc. (GRAL) vs Twist Bioscience Corporation (TWST)
- GRAIL, Inc. GRAL 117.81 −13.03%
- Twist Bioscience Corporation TWST 132.75 −8.13%
GRAIL, Inc. and Twist Bioscience Corporation are both Diagnostics & Research companies. Twist Bioscience Corporation is the larger, with a market value of $9.5B against $6.1B — 1.6× the size. GRAIL, Inc. grew revenue faster over the last twelve months: 23.1% against 19.2%. Twist Bioscience Corporation has the higher net margin (−31.7% vs −237.0%) and the lower return on invested capital (−30.8% vs −20.8%). Across the 17 metrics below, Twist Bioscience Corporation leads on 9 and GRAIL, Inc. on 8.
Valuation
Profitability
| Metric | GRAL | TWST | Diagnostics & Research median |
|---|---|---|---|
| Gross margin | (31.31%) | 51.97% | 50.89% |
| Operating margin | (338.40%) | (33.58%) | (8.57%) |
| Net margin | (236.95%) | (31.66%) | (6.37%) |
| Free cash flow margin | (179.21%) | (22.15%) | 0.00% |
| Return on equity | (16.12%) | (29.59%) | (2.92%) |
| Return on assets | (14.12%) | (20.78%) | (6.71%) |
| Return on invested capital | (20.79%) | (30.83%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack